Larimar Therapeutics shares are trading higher after the company announced that the FDA removed the partial clinical hold previously placed on the nomlabofusp clinical program.
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics shares are trading higher after the company announced that the FDA removed the partial clinical hold previously placed on the nomlabofusp clinical program.
May 20, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Larimar Therapeutics shares are trading higher after the FDA removed the partial clinical hold on the nomlabofusp clinical program.
The removal of the FDA's partial clinical hold is a significant positive development for Larimar Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100